Sandra N. Bulens

Sandra N. Bulens

Auto-generated profile, based on publicly available information

Sandra N. Bulens

Centers for Disease Control and Prevention, Atlanta, GA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Emerging Infectious Diseases
Verified
Journal Article
Open access
SBSandra N Bulens
Sandra N Bulens
SYSarah H Yi
Sarah H Yi
MWMaroya S Walters
Maroya S Walters
JJJesse T Jacob
Jesse T Jacob
CBChris Bower
Chris Bower
AKAlexander J Kallen
Alexander J Kallen
In healthcare settings, Acinetobacter spp. bacteria commonly demonstrate antimicrobial resistance, making them a major treatment challenge. Nearly half of Acinetobacter organisms from clinical cultures in the United States are nonsusceptible to carbapenem antimicrobial drugs. During 2012–2015, we conducted laboratory- and population-based surveillance in selected metropolitan areas in Colorado, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee to determine the incidence of carbapenem-nonsusceptible A. baumannii cultured from urine or normally sterile sites and to describe the demographic and clinical characteristics of patients and cases. We identified 621 cases in 537 patients; crude annual incidence was 1.2 cases/100,000 persons. Among 598 cases for which complete data were available, 590 (98.7%) occurred among patients with overnight stays in a hospital during the preceding year; 506 (84.6%) patients had an indwelling device. Although incidence was lower than for other healthcare-associated pathogens, cases were associated with substantial rates of illness and death.

28 July 2022 in American Journal of Infection Control
Verified
Journal Article
Open access
SBSandra N. Bulens
Sandra N. Bulens
HRHannah E. Reses
Hannah E. Reses
UAUzma A. Ansari
Uzma A. Ansari
JGJulian E. Grass
Julian E. Grass
CCClayton Carmon
Clayton Carmon
MWMaroya Spalding Walters
Maroya Spalding Walters
Carbapenem-resistant Enterobacterales (CRE) are usually healthcare-associated but are also emerging in the community. Active, population-based surveillance was conducted to identify case-patients with cultures positive for Enterobacterales not susceptible to a carbapenem (excluding ertapenem) and resistant to all third-generation cephalosporins tested at 8 US sites from January 2012 to December 2015. Medical records were used to classify cases as health care-associated, or as community-associated (CA) if a patient had no known health care risk factors and a culture was collected <3 days after hospital admission. Enterobacterales isolates from selected cases were submitted to CDC for whole genome sequencing. We identified 1499 CRE cases in 1194 case-patients; 149 cases (10%) in 139 case-patients were CA. The incidence of CRE cases per 100,000 population was 2.96 (95% CI: 2.81, 3.11) overall and 0.29 (95% CI: 0.25, 0.35) for CA-CRE. Most CA-CRE cases were in White persons (73%), females (84%) and identified from urine cultures (98%). Among the 12 sequenced CA-CRE isolates, 5 (42%) harbored a carbapenemase gene. Ten percent of CRE cases were CA; some isolates from CA-CRE cases harbored carbapenemase genes. Continued CRE surveillance in the community is critical to monitor emergence outside of traditional health care settings.

29 April 2024 in American Journal of Infection Control
Verified
Journal Article
Open access
SBSandra N. Bulens
Sandra N. Bulens
DCDavina Campbell
Davina Campbell
SMSusannah L. McKay
Susannah L. McKay
NVNicholas Vlachos
Nicholas Vlachos
ABAlex Burgin
Alex Burgin
JLJoseph D. Lutgring
Joseph D. Lutgring
Understanding the epidemiology of carbapenem-resistant A. baumannii complex (CRAB) and the patients impacted is an important step toward informing better infection prevention and control practices and improving public health response. Active, population-based surveillance was conducted for CRAB in 9 U.S. sites from January 1 to December 31, 2019. Medical records were reviewed, isolates were collected and characterized including antimicrobial susceptibility testing and whole genome sequencing. Among 136 incident cases in 2019, 66 isolates were collected and characterized; 56.5% were from cases who were male, 54.5% were from persons of Black or African American race with non-Hispanic ethnicity, and the median age was 63.5 years. Most isolates, 77.2%, were isolated from urine, and 50.0% were collected in the outpatient setting; 72.7% of isolates harbored an acquired carbapenemase gene (aCP), predominantly blaOXA-23 or blaOXA-24/40; however, an isolate with blaNDM was identified. The antimicrobial agent with the most in vitro activity was cefiderocol (96.9% of isolates were susceptible). Our surveillance found that CRAB isolates in the U.S. commonly harbor an aCP, have an antimicrobial susceptibility profile that is defined as difficult-to-treat resistance, and epidemiologically are similar regardless of the presence of an aCP.

23 December 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Closed access
JGJulian E Grass
Julian E Grass
SBSandra N Bulens
Sandra N Bulens
UAUzma A Ansari
Uzma A Ansari
NDNadezhda Duffy
Nadezhda Duffy
JJJesse T Jacob
Jesse T Jacob
AGAlice Y Guh
Alice Y Guh
Background: We investigated hospitalized carbapenem-resistant Enterobacterales (CRE) and extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E) cases with and without COVID-19, as identified through Emerging Infections Program surveillance in 10 sites from 2020 to 2022. Methods: We defined a CRE case as the first isolation of Escherichia coli, Enterobacter cloacae complex, Klebsiella aerogenes, K oxytoca, K pneumoniae, or K variicola resistant to any carbapenem. We defined an ESBL-E case as the first isolation of E coli, K pneumoniae, or K oxytoca resistant to any third-generation cephalosporin and nonresistant to all carbapenems tested. Specimens were drawn from a normally sterile site or urine among hospitalized residents of the surveillance area in a 30-day period. We defined COVID-19 as a positive SARS-CoV-2 test result (SC2+) within 14 days before CRE or ESBL-E specimen collection and performed multivariable logistic regression analyses. Results: Of 1595 CRE and 1866 ESBL-E hospitalized cases, 38 (2.4%) and 60 (3.2%), respectively, had a SC2+. Among these cases, a SC2+ was associated with intensive care unit admission (adjusted odds ratio [aOR], 1.69 [95% CI, 1.14–2.50]; aOR, 1.48 [95% CI, 1.03–2.12]) and 30-day mortality (aOR, 1.79 [95% CI, 1.22–2.64]; aOR, 1.94 [95% CI, 1.39–2.70]). Conclusions: CRE and ESBL-E infections among hospitalized patients with preceding COVID-19 were uncommon but had worse outcomes when compared with cases without COVID-19. COVID-19 prevention in patients at risk of CRE and ESBL-E infections is needed, as well as continued infection control measures and antibiotic stewardship for patients with COVID-19.